SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is currently experiencing intense market activity driven by a potent mix of surging AI-driven memory demand, recent bullish price target hikes from major analysts, and anticipation surrounding its upcoming earnings call. Investors are closely monitoring the stock as a key beneficiary of the AI infrastructure supercycle, while the community actively debates whether the stock's recent price appreciation is sustainable or if a short-term pullback is imminent amid broader geopolitical and sector-specific supply chain headwinds.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as investors digest the launch of BlackRock's new staked ETH ETF, with market participants closely monitoring institutional inflows and supply dynamics. The community remains divided between bullish sentiment fueled by potential supply shocks and institutional accumulation, and skeptical voices warning of broader macroeconomic risks and technical resistance levels.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following a strong quarterly earnings report that highlighted record revenue, significantly reduced debt, and a substantial pipeline of AI and GPU infrastructure opportunities. While the community is actively debating the company's valuation and long-term execution, investors are keenly focused on upcoming project milestones and the potential for increased momentum as the company expands its AI capacity.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is gaining significant traction as investors rally behind the project's roots as a classic internet meme, with the community actively promoting its presence on Solana and its restored comic-building tools. Supporters are emphasizing long-term conviction and 'bag-working' consistency, positioning the token as a primary competitor to newer, less-established meme projects.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is experiencing heightened investor volatility as market participants debate the impact of aggressive institutional Ethereum accumulation against concerns surrounding share dilution and short-selling reports. The community remains deeply divided, with bulls pointing to the company's substantial cash and Ethereum reserves as structural support, while bears focus on the stock's disconnect from underlying asset performance and management's capital-raising activities.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corporation is experiencing increased attention following a prime contract award from Belgian Defence to construct the country's first national security satellite, with community members debating the long-term revenue impact of these strategic wins. Investors remain focused on the firm's expansion into defense and space-based manufacturing, balancing optimism about their technological pipeline against ongoing volatility and institutional selling pressures.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as momentum builds ahead of next week's OFC conference, with investors closely watching for potential product integration announcements and partnership updates following positive industry sentiment. While community members remain focused on the company's potential to scale its optical interposer technology for AI infrastructure, the stock's recent volatility and high trading volume reflect intense speculation regarding whether the company will soon secure significant commercial orders.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging after announcing a strategic partnership and $2 billion investment from NVIDIA, which bolsters its capacity to scale hyperscale AI infrastructure and secures its position as a key player in the agentic AI compute market. Investors are actively discussing the company's aggressive capacity build-out plans, the validation provided by major tech partners, and the potential for a significant short squeeze as the stock breaks out of recent resistance levels.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as the market reacts to the Trump administration's use of the Defense Production Act to prioritize the restart of the Santa Ynez Unit oil pipeline, a move intended to bolster domestic energy supply. While investors are actively debating the potential for a massive short squeeze due to high short interest and federal support, others remain cautious of ongoing legal challenges from California state authorities and potential liquidity hurdles.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is experiencing significant momentum driven by the recent US patent allowance for its lead ADHD drug, CTx-1301, and heightened anticipation ahead of the May 31, 2026, PDUFA target date. The community is actively discussing the stock's low float and strong institutional accumulation, with many investors anticipating a major price rally as the company moves toward a high-value commercial launch in a multi-billion dollar market.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS

Cassava Sciences (NASDAQ:SAVA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus...

Investors Purchase Large Volume of Cassava Sciences Call Options (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 12,849 call options on the stock. This is an...

Cassava Sciences (NASDAQ:SAVA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised shares of Cassava Sciences from a "sell" rating to a "hold" rating in a research note on Sunday...

Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday

Cassava Sciences (NASDAQ:SAVA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 3. (View Earnings Report at...

Cassava Sciences (NASDAQ:SAVA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Cassava Sciences from a "hold" rating to a "sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;</li><li>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.</li><li>Cassava previously reached a settlement with the SEC regarding the allegations and paid a monetary penalty without admitting or denying the SEC’s allegations.</li></ul>&nbsp;Cassava Sciences, Inc. (SAVA) said on Thursday that the U.S. Department of Justice has closed its probe into the company over allegations of research misconduct pertaining to its drug Simufilam.The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” &nbsp;CEO Richard J. Barry said.Shares of the company traded 2% lower at the time of writing.<h2 class="st-heading-2">Settlement With SEC</h2>Previously in Sept. 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the allegations and paid a monetary penalty without admitting or denying the claims. &nbsp;The SEC charged Cassava and two former executives — founder and former CEO Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns — with making misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, Simufilam.The regulator alleged that the company claimed the drug "significantly improved patient cognition," while failing to disclose that full patient data showed "no measurable cognitive improvement" in episodic memory.Hoau-Yan Wang, a professor at the City University of New York Medical School, who worked with Cassava to develop the drug, was also charged with manipulating trial data.<h2 class="st-heading-2">Simufilam Now</h2>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.The decision to discontinue the Alzheimer’s program followed the drug’s failure to show clinical benefit in a late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume improved from ‘low’ to ‘normal’ levels.A Stocktwits user expressed doubts regarding the allegations raised against the company and said they will not invest in it again.<stembedurl>https://www.stocktwits.com/2bitinvestor/message/645330236</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/btm-stock-falls-reverse-split/cZRkTKdR4D4">BTM Stock Pares Early Losses After Company Announces 1-For-7 Reverse Stock Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration a Cassava Sciences, Inc. logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program

The probes into the company by both the DOJ and the SEC have now been closed. 

Equity

Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Cassava Sciences from a "sell" rating to a "hold" rating in a report on Sunday...

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO...

Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Trading Down 23.9% - Here's What Happened...

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SAVA News

SAVACassava Sciences Inc